GAROFALO HEALTH CARE S.P.A.

Shareholders of Garofalo Health Care S.p.A.

As an Italian company listed on Euronext STAR Milan, Garofalo Health Care S.p.A. is required under CONSOB rules to publicly disclose only shareholders whose stake exceeds 5% of share capital; it does not publish a complete shareholder register. Based on the most recent publicly available snapshot reviewed for this profile (dated 8 January 2026), the disclosed holders above the threshold were: Larama ’98 S.p.A., holding approximately 50.46% of ordinary share capital; Maria Laura Garofalo, holding a further approximately 12.64% directly in her own name; and Fondazione Enasarco, holding approximately 5.28%. An earlier CONSOB-linked snapshot also recorded a stake held by Ente Nazionale di Previdenza ed Assistenza dei Medici (ENPAM) close to 5%, but its current size was not independently confirmed for this profile. The remainder of capital is free float traded on Euronext STAR Milan and is not attributed to named holders in public disclosures. The registry snapshot on file for this company returned no shareholder listing; that reflects the Italian disclosure regime described above rather than an absence of shareholders.

Ultimate beneficial ownership

Larama ’98 S.p.A., the direct controlling shareholder, is itself administered by a member of the Garofalo family: publicly available company information identifies Prof. Mariano Garofalo as its sole administrator. Maria Laura Garofalo, the company’s Chief Executive Officer, is reported to hold a combined majority interest in the company’s capital directly and through Larama ’98 S.p.A. However, a fully sourced, single-dated ownership chain sufficient to calculate one verified effective UBO percentage for the underlying family was not located in the sources reviewed, so no calculated effective percentage is presented here.

Data availability

Shareholder disclosure for Garofalo Health Care S.p.A. is categorised as Major shareholders only: CONSOB and Euronext STAR Milan disclosure rules require publication of stakes above 5% of capital, not a full shareholder register, so minority holders below that threshold cannot be identified from public sources.

Directors and officers of Garofalo Health Care S.p.A.

Garofalo Health Care S.p.A. is administered by an 11-member Board of Directors, appointed by the shareholders’ meeting on 29 April 2024 for a term running to the approval of the financial statements for the year ending 31 December 2026, per the company’s own governance disclosures. The Board comprises four executive directors, Chairman Alessandro Maria Rinaldi, Chief Executive Officer Maria Laura Garofalo, and Executive Directors Claudia Garofalo and Guido Dalla Rosa Prati; two non-executive directors, Giuseppe Giannasio and Alessandra Rinaldi Garofalo; and five independent directors, Luca Matrigiani, Federico Ferro-Luzzi, Giancarla Branda, Franca Brusco and Alberto Oliveti. A separate Board of Statutory Auditors was appointed the same day for the same term: Sonia Peron (Chairman), Alessandro Musaio and Francesca Di Donato (standing auditors), and Andrea Bonelli and Marco Salvatore (alternate auditors). The company’s own investor-relations materials additionally identify Luigi Celentano as Group Chief Financial Officer. Nationality is not disclosed for any of these individuals in the sources reviewed and is reported here as Not disclosed.

Recent officer changes

The current Board of Directors and Board of Statutory Auditors were both installed at the shareholders’ meeting of 29 April 2024, replacing the boards previously in office, which, per a CONSOB governance snapshot dated 31 December 2023, had also included directors Nicoletta Mincato and Javier De La Rica Aranguren, neither of whom appears on the board elected in 2024.

Data availability

Officer information for Garofalo Health Care S.p.A. is categorised as Partial: the company’s own investor-relations site publishes current Board and Statutory Auditor rosters with appointment dates but not nationality or a complete historical appointment record for every past officer. The registry snapshot on file for this company lists only four officer records, understating the size of the actual 11-member Board; one of those four records appears to be a duplicate or corrupted entry (first name recorded as “Attorney” attached to Maria Laura Garofalo’s surname and birth data) rather than a distinct officer, and should not be read as a separate individual.

Group structure of Garofalo Health Care S.p.A.

Garofalo Health Care S.p.A. sits at the top of its own corporate group as the listed parent holding company; no external parent or controlling corporate entity was identified in the sources reviewed (its largest shareholder, Larama ’98 S.p.A., is a shareholder, not a parent company shown in registry data). The group comprises more than twenty-five Italian operating subsidiaries engaged in hospital, clinic, diagnostic and rehabilitation services, most held directly and some through intermediate holding subsidiaries. The company’s own “The Group” webpage and the underlying registry linkage data are broadly consistent as to which entities are included, though neither source published individual ownership percentages as of the retrieval date.

Verified corporate relationships

Operating subsidiaries identified from the company’s own group disclosures and cross-checked registry data include, among others: Sanatorio Triestino S.p.A. (with its own subsidiary, Terme del Friuli Venezia Giulia S.r.l.), Rugani Hospital S.r.l., FI.D.ES. Medica S.r.l. (Gruppo Fides, with subsidiaries Centro di Riabilitazione S.r.l. and Ro.E Mar. S.r.l.), Gruppo Veneto Diagnostica e Riabilitazione S.r.l., Istituto Raffaele Garofalo S.r.l., Casa di Cura Prof. Nobili S.r.l., Casa di Cura Villa Berica S.r.l., Casa di Cura Villa Garda S.r.l., Domus Nova S.r.l., Poliambulatorio Dalla Rosa Prati S.r.l., Villa von Siebenthal S.r.l., Aurelia Hospital S.r.l. (parent of European Hospital S.p.A., Casa di Cura Città di Roma S.r.l. and AXA Residence S.p.A., with European Hospital in turn holding Finaur S.r.l. and Casa di Cura S. Antonio da Padova S.r.l.), C.M.S.R. Veneto Medica S.r.l., Hesperia Hospital Modena S.r.l. (with subsidiary Aesculapio S.r.l.), Xray One S.r.l., Sanimedica S.r.l., Centro Medico San Biagio S.r.l., Ospedali Privati Riuniti S.r.l., Clinica San Francesco S.r.l., Bimar S.r.l. and Garofalo Health Care Real Estate S.p.A. All are Italian-registered entities; ownership percentages within the chain were not disclosed in the sources reviewed and are not presented here as verified figures.

Recent structural changes

The company’s own announcements record the acquisition of Casa di Cura Città di Roma (announced July 2025) and, on the shareholder rather than subsidiary side, the January 2024 exit of private-equity investor Peninsula Capital from Garofalo Health Care S.p.A.’s own shareholder base.

Data availability

Corporate-linkage information for this group is categorised as Full as to the identity of operating subsidiaries, consistently confirmed across the company’s own website and the underlying registry linkage data, but Partial as to ownership percentages, which were not published for individual subsidiaries in the sources reviewed.